Literature DB >> 15161058

Human beta-defensin-2 in oral cancer with opportunistic Candida infection.

Jens Eduard Meyer1, Jürgen Harder, Tibor Görögh, Jan Bernd Weise, Sabine Schubert, Dirk Janssen, Steffen Maune.   

Abstract

Candida albicans (CA) is a frequent opportunistic pathogen in cancer patients. Usually, human surfaces are protected, apart from physical barriers, by the production of human beta-defensins (hBD). hBD-2 shows a potent antimicrobial activity against CA. We therefore investigated whether CA induces hBD-2 expression in primary oral cells and if immunosuppressive betamethasone alters hBD-2 expression. Additionally, we studied, whether a lack of hBD-2 expression could explain opportunistic infection of tonsillar cancer. Primary oral epithelial cells and fibroblasts were stimulated with Candida albicans in a time- and dose-dependent manner with or without betamethasone preincubation. Total RNA from oral cells and specimens was isolated and hBD-2 expression was analyzed by semiquantitative RT-PCR. Our data demonstrate that opportunistic CA induced hBD-2 expression in a time- and dose-dependent manner, suggesting hBD-2 to be a fast antifungal, epithelia-derived immune response. Treatment with glucocorticoid could lead to diminished innate immunity based on suppression of inducible AP. Malignant transformation induces alteration of hBD-2 expression and leads to a reduced hBD-2 expression and subsequentially to Candida colonization on oral SCCs.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15161058

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  12 in total

Review 1.  Antimicrobial anxiety: the impact of stress on antimicrobial immunity.

Authors:  Katherine A Radek
Journal:  J Leukoc Biol       Date:  2010-05-04       Impact factor: 4.962

2.  Capacity of human beta-defensin expression in gene-transduced and cytokine-induced cells.

Authors:  Chunyi Yin; Hoa N Dang; Hai-Bo Zhang; Farzad Gazor; Daniel Kim; Ole E Sorensen; George T-J Huang
Journal:  Biochem Biophys Res Commun       Date:  2005-11-15       Impact factor: 3.575

3.  Transcriptional responses of candida albicans to epithelial and endothelial cells.

Authors:  Hyunsook Park; Yaoping Liu; Norma Solis; Joshua Spotkov; Jessica Hamaker; Jill R Blankenship; Michael R Yeaman; Aaron P Mitchell; Haoping Liu; Scott G Filler
Journal:  Eukaryot Cell       Date:  2009-08-21

Review 4.  Role of beta-defensins in oral epithelial health and disease.

Authors:  Yoshihiro Abiko; Masto Saitoh; Michiko Nishimura; Mami Yamazaki; Daisuke Sawamura; Tohru Kaku
Journal:  Med Mol Morphol       Date:  2007-12-21       Impact factor: 2.309

Review 5.  Antimicrobial peptides and their potential application in inflammation and sepsis.

Authors:  Tobias Schuerholz; Klaus Brandenburg; Gernot Marx
Journal:  Crit Care       Date:  2012-12-12       Impact factor: 9.097

6.  Inducibility of the endogenous antibiotic peptide beta-defensin 2 is impaired in patients with severe sepsis.

Authors:  Malte Book; QiXing Chen; Lutz E Lehmann; Sven Klaschik; Stefan Weber; Jens-Christian Schewe; Markus Luepertz; Andreas Hoeft; Frank Stuber
Journal:  Crit Care       Date:  2007       Impact factor: 9.097

Review 7.  How Chemotherapy Increases the Risk of Systemic Candidiasis in Cancer Patients: Current Paradigm and Future Directions.

Authors:  Flora Teoh; Norman Pavelka
Journal:  Pathogens       Date:  2016-01-15

Review 8.  Perspectives for clinical use of engineered human host defense antimicrobial peptides.

Authors:  María Eugenia Pachón-Ibáñez; Younes Smani; Jerónimo Pachón; Javier Sánchez-Céspedes
Journal:  FEMS Microbiol Rev       Date:  2017-05-01       Impact factor: 16.408

9.  Human beta-defensin 3 contributes to the carcinogenesis of cervical cancer via activation of NF-κB signaling.

Authors:  Dan Xu; Bing Zhang; Chongbing Liao; Wei Zhang; Weijia Wang; Ying Chang; Yongping Shao
Journal:  Oncotarget       Date:  2016-11-15

Review 10.  Defensins: A Double-Edged Sword in Host Immunity.

Authors:  Dan Xu; Wuyuan Lu
Journal:  Front Immunol       Date:  2020-05-07       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.